• Organon & Co OGN.N reported quarterly adjusted earnings of 90 cents​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of 88 cents. The mean expectation of eight analysts for the quarter was for earnings of 87 cents per share. Wall Street expected results to range from 82 cents to 93 cents per share.

• Revenue fell 0.4% to $1.59 billion from a year ago; analysts expected $1.59 billion.

• Organon & Co's reported EPS for the quarter was 42 cents​.

• The company reported quarterly net income of $109 million.

• Organon & Co shares had fallen by 1.5% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 6.3% in the last three months.​

• In the last 30 days, two analysts negatively revised earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 4 "strong buy" or "buy," 4 "hold" and 2 "sell" or "strong sell."

• The average consensus recommendation for the pharmaceuticals peer group is also "hold"

Wall Street's median 12-month price target for Organon & Co is $20.00

This summary was machine generated from LSEG data February 13 at 02:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)